Aviado · Research
Longevity Daily
Thursday, November 5, 2026
Listen
Today's Brief
Today's lead is a rare, tangible finding: University of Oulu researchers showed that lying on a vibrating mattress for 40 minutes, combined with nitric oxide pills, significantly clears Alzheimer's-linked proteins from the waking brain. Life Biosciences has released the first-ever human data from an age-reversal gene therapy, and a peer-reviewed RCT confirms that NOVOS Core meaningfully improves vascular health in healthy adults over 40. Aviado Research examines lutein's anti-inflammatory clinical evidence at 20 mg/day, while The Economist delivers a pointed reality check on whether GLP-1 drugs can truly earn the longevity drug label.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Vibrating Mattress + Nitric Oxide Pills Flush Alzheimer's Protein From the Waking Brain
Researchers from the University of Oulu had 29 healthy adults lie on a vibrating mattress for 40 minutes while taking two nitric oxide-releasing pills — and the combination significantly boosted the brain's clearance of amyloid-beta, an Alzheimer's-linked protein, through the glymphatic waste-disposal system. The vasomechanical approach works by temporarily lowering blood pressure while stimulating the body's natural brain-flushing mechanism, essentially mimicking the deep-sleep waste clearance we lose with age. This is a small pilot study in healthy adults that needs replication and long-term outcome data — but as non-invasive interventions go, a vibrating mattress and an over-the-counter pill combination is about as accessible as longevity medicine gets. Watch this space closely.
Read more →Could Hormone Therapy Lower Your Alzheimer's Risk? Scientists Are Finally Taking the Question Seriously
The Washington Post examines growing scientific interest in whether hormone replacement therapy might protect older women's brains from Alzheimer's and dementia. Estrogen's neuroprotective role is biologically plausible — it influences inflammation, amyloid clearance, and synaptic function — but robust clinical evidence from randomized trials is still accumulating and results have historically been mixed. For women navigating perimenopause and menopause, this is precisely the kind of question worth raising with your doctor before the window may close.
Read more →Supplements & Compounds
NOVOS Core Passes Its First Randomized Trial: Better Blood Vessels, Lower Blood Pressure in Adults 40+
A randomized, double-blind, placebo-controlled trial led by the University of Surrey found that NOVOS Core — a 12-ingredient longevity supplement — significantly improved blood vessel function, arterial flexibility, and reduced systolic blood pressure in healthy adults aged 40 and over, with no significant effect on blood lipid levels. This matters because most longevity supplements on the market have never been tested in a peer-reviewed RCT in healthy (non-patient) adults — which is exactly the population most of our readers belong to. The results are published in a peer-reviewed journal, making this one of the more credible data points in the multi-ingredient longevity supplement space.
Read more →David Sinclair's Favorite Mitochondria Peptide Got FDA Approval — Here's What You Should Know
SS-31 (now sold as Forzinity), a mitochondria-targeting peptide developed over 20 years at MIT, received FDA approval in 2025 for Barth syndrome — a rare genetic heart disease — and David Sinclair has flagged its broader anti-aging potential given that cardiolipin, the molecule it targets, declines with age across the general population. This is not a supplement you can easily obtain, and it is not approved for healthy aging, but the underlying science linking mitochondrial cardiolipin decline to aging is well-established. Worth tracking as off-label interest from longevity clinics grows.
Read more →Lutein Tackles Inflammation at the Source — Here's What the RCT Evidence Actually Shows
Aviado Research examines the mechanistic and clinical case for lutein as an anti-inflammatory supplement: at 20 mg/day, RCT data shows significant reductions in C-reactive protein (CRP) and malondialdehyde (MDA), key markers of oxidative stress and systemic inflammation. The mechanism is well-characterized — lutein neutralizes reactive oxygen species and downregulates IL-6 and TNF-α — but not all studies replicate these effects, and individual responses vary. If you already track biomarkers like CRP, this is one of the more evidence-grounded additions to a longevity stack, with an optimal dose range of 10–20 mg/day in free or highly bioavailable form.
Read the full Aviado analysis →Research & Papers
First Human Data From an Age-Reversal Gene Therapy Is In — and It's Cautiously Encouraging
Life Biosciences has released what appears to be the first-ever human trial data for an age-reversal gene therapy: two of three patients showed measurable improvement, and no adverse events were reported. The n=3 sample is not a clinical trial by any standard, and results cannot be generalized — but as a proof of concept that the approach doesn't cause harm and may produce a meaningful signal, it marks a symbolic milestone in longevity medicine. Dr. Robert Lufkin provides accessible context for why this moment matters even without statistical power.
Read more →Your Bones Are an Anti-Aging Organ — and a New Cell Metabolism Study Explains Why
A study published in Cell Metabolism in October 2026 suggests the skeleton may be one of the body's most underappreciated anti-aging organs, actively secreting hormones and signaling molecules that influence systemic aging rates across tissues. The research challenges the long-held assumption that bones are passive structural tissue, pointing instead to their role in metabolic and longevity signaling networks. If confirmed and extended in humans, this could open an entirely new class of interventions targeting bone health not just for fracture prevention, but for whole-body longevity.
Read more →Metformin Added Nothing to Exercise in a Lancet Trial — Intensive Lifestyle Won on Its Own
A Lancet Healthy Longevity abstract reveals that adding metformin to an intensive lifestyle program produced essentially zero additional benefit on physical performance scores at six months (p=0.92), while intensive lifestyle alone beat basic dietary education by 2.5 points with both groups on metformin. For the longevity-minded audience currently stacking metformin alongside serious exercise and diet protocols, this is a data point that warrants a conversation with your physician. The unresolved question of whether metformin blunts exercise adaptations — raised by earlier research — stays very much open.
Read more →Lifestyle & Nutrition
High-Carb Diet Improved Biological Age Markers in Older Adults Within 4 Weeks, Study Finds
A University of Sydney study found that older adults placed on a low-fat, high-carbohydrate omnivorous diet showed measurable improvements in biological age markers in just four weeks — a counterintuitive finding in an era that heavily promotes low-carb and ketogenic protocols for longevity. The study is short-term and doesn't track hard long-term outcomes, but it raises important questions about whether blanket low-carb advice is appropriate for all older adults. Important nuance: the high-carb arm here almost certainly emphasizes whole food carbohydrates, not refined sugar or ultra-processed starches.
Read more →Industry & Policy
Novo and Lilly Want GLP-1s to Be the First Longevity Drugs. The Economist Isn't Buying It Yet
The Economist's podcast examines the race to position GLP-1 receptor agonists like semaglutide and tirzepatide as the first true longevity pharmaceuticals, with early data pointing to reduced cardiovascular events and meaningful metabolic improvements. The critical caveat: virtually all existing evidence comes from people with specific diseases — obesity, diabetes, heart failure — not healthy adults seeking lifespan extension, and no robust clinical trials in that population have completed. Until that evidence exists, calling GLP-1s longevity drugs is, as the podcast puts it, premature and in need of a pinch of salt.
Read more →